ANKL
MCID: NTR003
MIFTS: 47

Natural Killer Cell Leukemia (ANKL) malady

Categories: Rare diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Natural Killer Cell Leukemia

Aliases & Descriptions for Natural Killer Cell Leukemia:

Name: Natural Killer Cell Leukemia 12 14
Aggressive Nk-Cell Leukemia 12 56
Ankl 50 29
Leukemia, Natural Killer Cell Large Granular Lymphocytic 69
Large Granular Lymphocyte Leukemia, Nk-Cell Type 12
Nk-Cell Large Granular Lymphocyte Leukemia 56
Aggressive Natural Killer Cell Leukemia 50
Aggressive Natural Killer-Cell Leukemia 69
Leukemia, Large Granular Lymphocytic 69
Aggressive Nk Cell Leukemia 50
Aggressive Nk-Cell Lymphoma 56
Nk-Cell Lgl Leukemia 56
Ankcl 56

Characteristics:

Orphanet epidemiological data:

56
aggressive nk-cell leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:1035
ICD10 33 C94.8
NCIt 47 C8647
SNOMED-CT 64 128833001
Orphanet 56 ORPHA86873
UMLS via Orphanet 70 C1292777
ICD10 via Orphanet 34 C94.7
UMLS 69 C1292777

Summaries for Natural Killer Cell Leukemia

MalaCards based summary : Natural Killer Cell Leukemia, also known as aggressive nk-cell leukemia, is related to tenosynovitis of foot and ankle and ankle defects short stature, and has symptoms including fever An important gene associated with Natural Killer Cell Leukemia is GZMB (Granzyme B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and NF-kappaB Signaling. The drugs Aldesleukin and Histamine have been mentioned in the context of this disorder. Affiliated tissues include nk cells, bone and bone marrow.

Related Diseases for Natural Killer Cell Leukemia

Diseases related to Natural Killer Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
id Related Disease Score Top Affiliating Genes
1 tenosynovitis of foot and ankle 11.8
2 ankle defects short stature 11.8
3 hemarthrosis 11.4
4 arthropathy 11.4
5 pigmented villonodular synovitis 11.1
6 clubfoot 11.0
7 tarsal tunnel syndrome 11.0
8 talipes equinovarus 11.0
9 foot drop 10.9
10 septic arthritis 10.9
11 exostosis 10.9
12 hemophilia 10.9
13 accessory navicular bone 10.9
14 osteonecrosis 10.9
15 buschke-ollendorff syndrome 10.9
16 lichen planus 10.9
17 ulcer of lower limbs 10.8
18 mesomelic dysplasia, kantaputra type 10.8
19 behcet's syndrome arthropathy 10.8
20 liang distal myopathy 10.8
21 hand-foot-uterus syndrome 10.7
22 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 10.7
23 bethlem myopathy 1 10.7
24 osteochondritis dissecans, short stature, and early-onset osteoarthritis 10.7
25 patellar tendinitis 10.7
26 tarsal-carpal coalition syndrome 10.7
27 emery-dreifuss muscular dystrophy 10.7
28 decubitus ulcer 10.7
29 contractural arachnodactyly, congenital 10.7
30 epidermolysis bullosa simplex, sutosomal recessive 2 10.7
31 leukemia 10.6
32 epiphyseal dysplasia, multiple, 5 10.5
33 epiphyseal dysplasia, multiple, 6 10.5
34 repetitive motion disorders 10.5
35 erythermalgia, primary 10.5
36 bethlem myopathy 2 10.5
37 meleda disease 10.5
38 repetitive stress injuries 10.5
39 neuropathy, hereditary sensory and autonomic, type ia 10.5
40 arthrogryposis multiplex congenita, neurogenic type 10.5
41 chondrodysplasia punctata 1, x-linked 10.5
42 pulmonary hypertension, familial primary, 1, with or without hht 10.5
43 tendons, extensor, of fingers, anomalous insertion of 10.5
44 proximal symphalangism 10.5
45 atopic dermatitis 10.5
46 intermittent hydrarthrosis 10.5
47 acrocapitofemoral dysplasia 10.5
48 adie pupil 10.5
49 vulvovaginal gingival syndrome 10.5
50 lipedema 10.5

Graphical network of the top 20 diseases related to Natural Killer Cell Leukemia:



Diseases related to Natural Killer Cell Leukemia

Symptoms & Phenotypes for Natural Killer Cell Leukemia

UMLS symptoms related to Natural Killer Cell Leukemia:


fever

Drugs & Therapeutics for Natural Killer Cell Leukemia

Drugs for Natural Killer Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 4,Phase 2,Phase 1 85898-30-2, 110942-02-4
2
Histamine Approved, Investigational Phase 4,Phase 1,Phase 2 75614-87-8, 51-45-6 774
3 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
7
Histamine Phosphate Phase 4,Phase 1,Phase 2 51-74-1 65513
8 Interleukin-2 Phase 4,Phase 2,Phase 1
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Cefepime Approved Phase 3 88040-23-7 5479537
11
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
12
Ofloxacin Approved Phase 3 82419-36-1 4583
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
15
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
16
Vidarabine Approved Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
17
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
18
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
19
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
20
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
21
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
22
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
23
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
24
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
27
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
28
Ondansetron Approved Phase 3 99614-02-5 4595
29
Dalteparin Approved Phase 3 9041-08-1
30
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
31
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
32
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
33
Morphine Approved, Investigational Phase 3,Phase 2,Phase 1 57-27-2 5288826
34
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
35
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
36
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
37
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
38
Clofarabine Approved, Investigational Phase 3,Phase 2,Phase 1 123318-82-1 119182
39
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
40
Dasatinib Approved, Investigational Phase 3,Phase 1,Phase 2 302962-49-8 3062316
41
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
42
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
43
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
44
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
45
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
46
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
47
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
48
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
49
Daunorubicin Approved Phase 3,Phase 2 20830-81-3 30323
50
Thioguanine Approved Phase 3 154-42-7 2723601

Interventional clinical trials:

(show top 50) (show all 284)
id Name Status NCT ID Phase
1 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4
2 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
10 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
11 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
12 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
13 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
14 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
15 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
16 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed NCT00412360 Phase 3
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
18 Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00703820 Phase 3
19 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00549848 Phase 3
20 T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Terminated NCT00306332 Phase 3
21 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
22 CNDO-109-AANK for AML in First Complete Remission (CR1) Unknown status NCT01520558 Phase 1, Phase 2
23 Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells Unknown status NCT01220544 Phase 1, Phase 2
24 The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells Unknown status NCT01868490 Phase 1, Phase 2
25 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Unknown status NCT00691015 Phase 2
26 Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer Completed NCT00031980 Phase 2
27 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents Completed NCT00003635 Phase 2
28 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2
29 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
30 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
31 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
32 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2
33 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
34 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
35 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
36 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
37 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
38 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2
39 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
40 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2
41 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2
42 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2
43 "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia Completed NCT02074657 Phase 2
44 Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation Completed NCT01795378 Phase 1, Phase 2
45 Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant Completed NCT00526292 Phase 2
46 Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00274846 Phase 2
47 Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant Completed NCT00303667 Phase 1, Phase 2
48 Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy Completed NCT00815321 Phase 2
49 Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed NCT00394381 Phase 1, Phase 2
50 Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies Completed NCT01181258 Phase 2

Search NIH Clinical Center for Natural Killer Cell Leukemia

Genetic Tests for Natural Killer Cell Leukemia

Genetic tests related to Natural Killer Cell Leukemia:

id Genetic test Affiliating Genes
1 Abnormality of the Ankles 29

Anatomical Context for Natural Killer Cell Leukemia

MalaCards organs/tissues related to Natural Killer Cell Leukemia:

39
Nk Cells, Bone, Bone Marrow, T Cells, Myeloid

Publications for Natural Killer Cell Leukemia

Articles related to Natural Killer Cell Leukemia:

(show top 50) (show all 65)
id Title Authors Year
1
EBV-associated aggressive natural killer cell leukemia. ( 28092886 )
2016
2
Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites. ( 26975038 )
2016
3
Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. ( 27483437 )
2016
4
L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. ( 27091029 )
2016
5
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. ( 27566560 )
2016
6
Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemia. ( 25694835 )
2015
7
Six cases of aggressive natural killer-cell leukemia in a Chinese population. ( 25031771 )
2014
8
Aggressive natural killer-cell leukemia: classical presentation of a rare disease. ( 25118753 )
2014
9
Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. ( 24524877 )
2014
10
Rare aggressive natural killer cell leukemia presented with bone marrow fibrosis - a diagnostic challenge. ( 25126488 )
2014
11
Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. ( 23772641 )
2013
12
A probable identical Epstein-Barr virus clone-positive composite lymphoma with aggressive natural killer-cell leukemia and cytotoxic T-cell lymphoma. ( 24427365 )
2013
13
Aggressive natural killer-cell leukemia with jaundice and spontaneous splenic rupture: a case report and review of the literature. ( 23510456 )
2013
14
Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. ( 23181473 )
2013
15
Adult aggressive natural killer cell leukemia. ( 23241562 )
2013
16
Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. ( 22891745 )
2013
17
Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. ( 22360679 )
2012
18
Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication. ( 23037625 )
2012
19
Collapsing glomerulopathy associated with natural killer cell leukemia: a case report and review of the literature. ( 21908087 )
2011
20
Sustained CR of refractory aggressive natural killer cell leukemia following unrelated cord blood transplantation. ( 20676148 )
2010
21
Epstein-Barr virus-associated proliferative disorder presenting as Hodgkin's lymphoma and developing as aggressive natural killer-cell leukemia 19 years later: a case report of composite lymphoma. ( 19269751 )
2009
22
A case of natural killer cell leukemia misdiagnosed as tuberculous lymphadenopathy. ( 19571615 )
2009
23
Frequent CD7 antigen loss in aggressive natural killer-cell leukemia: a useful diagnostic marker. ( 20046078 )
2009
24
Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis? ( 19153474 )
2008
25
Aggressive natural killer cell leukemia presenting with hemophagocytic lymphohistiocytosis. ( 17853464 )
2008
26
Cytogenetic characterization of natural killer cell leukemia. ( 18503833 )
2008
27
Precursor natural killer cell leukemia. ( 17417789 )
2008
28
Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature. ( 17261497 )
2007
29
Aggressive natural killer cell leukemia in a patient with common variable immunodeficiency syndrome. ( 16785152 )
2006
30
Retroviral expression screening of oncogenes in natural killer cell leukemia. ( 15978945 )
2005
31
Prolonged treatment response in aggressive natural killer cell leukemia. ( 16019515 )
2005
32
Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. ( 14961041 )
2004
33
Unusual lymphoma manifestations: case 1. Natural killer cell leukemia with dermal erythema and vascular epidermal growth factor production. ( 14752078 )
2004
34
Marked elevation of soluble fas ligand and cytokine secretion after splenectomy in aggressive natural killer cell leukemia/lymphoma. ( 15512819 )
2004
35
Aggressive Natural Killer-Cell Leukemia: report of five cases and review of the literature. ( 15621755 )
2004
36
Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature. ( 15360011 )
2004
37
Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. ( 12943609 )
2003
38
Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma. ( 12543867 )
2003
39
Comprehensive cytogenetic study by spectral karyotyping on blastic natural killer cell leukemia/lymphoma. ( 11891818 )
2002
40
Aggressive natural killer cell leukemia: clinical features and treatment outcome. ( 12495907 )
2002
41
Myeloid natural killer cell leukemia resembling a variant of acute promyelocytic leukemia. ( 11454535 )
2001
42
Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. ( 11568749 )
2001
43
Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia. ( 11779295 )
2001
44
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. ( 10803505 )
2000
45
Long-term remission induced by corticosteroids, cyclophosphamide, and methotrexate in a patient with natural killer cell leukemia. ( 10696134 )
2000
46
Aggressive natural killer cell leukemia/lymphoma: a comprehensive cytogenetic study by spectral karyotyping. ( 11043424 )
2000
47
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. ( 10803526 )
2000
48
Epstein-Barr virus-infected natural killer cell leukemia. ( 11426629 )
2000
49
Interferon-gamma prevents apoptosis in Epstein-Barr virus-infected natural killer cell leukemia in an autocrine fashion. ( 10233902 )
1999
50
Blastoid natural killer cell leukemia. ( 10439811 )
1999

Variations for Natural Killer Cell Leukemia

Expression for Natural Killer Cell Leukemia

Search GEO for disease gene expression data for Natural Killer Cell Leukemia.

Pathways for Natural Killer Cell Leukemia

GO Terms for Natural Killer Cell Leukemia

Cellular components related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.02 B3GAT1 EPO IL4 IL7 MPO

Biological processes related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.63 EPO IL4 IL7
2 response to nutrient GO:0007584 9.43 EPO IL4
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.4 EPO IL4
4 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.37 IL4 IL7
5 positive regulation of B cell proliferation GO:0030890 9.32 IL4 IL7
6 positive regulation of activated T cell proliferation GO:0042104 9.26 EPO IL4
7 positive regulation of T cell differentiation GO:0045582 9.16 IL4 IL7
8 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 8.96 EPO IL4
9 negative regulation of apoptotic process GO:0043066 8.92 EPO IL4 IL7 MPO

Molecular functions related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 8.62 IL4 IL7

Sources for Natural Killer Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....